Raymond James Financial
CSTL icon

Raymond James Financial’s Castle Biosciences CSTL Stock Holding History

Raymond James Financial’s Portfolio CSTL Stock Details CSTL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-5,238
Closed -$204K – 5329
2025
Q4 		$204K Buy
+5,238
New +$169K ﹤0.01% 4779
2025
Q3 		– Sell
-662
Closed -$13.5K – 5358
2025
Q2 		$13.5K Buy
+662
New +$12.3K ﹤0.01% 5771

Other funds holding CSTL

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
Principal Financial Group
Principal Financial Group Des Moines, Iowa $204B AUM 27.99% 1-Year Est. Return
PCM
Portolan Capital Management Boston, Massachusetts $1.88B AUM 115.74% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
SPPAM
Summit Partners Public Asset Management Boston, Massachusetts $3.72B AUM 162.29% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
Allianz Asset Management
Allianz Asset Management Munich, Germany $95.4B AUM 38.74% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Raymond James Financial's CSTL Position: Q1 2026 in Review

Raymond James Financial sold out of Castle Biosciences (CSTL) in Q1 2026, closing a stake of 5,238 shares — an estimated $204K sold.

Raymond James Financial first reported a position in CSTL in Q2 2025 and held it in 2 quarters. The position peaked at $204K in Q4 2025. 186 funds tracked by Wall St. Rank hold CSTL as of Q1 2026.

  • Raymond James Financial reported no remaining Castle Biosciences position as of Q1 2026 after selling out during the quarter.
  • Raymond James Financial sold 5,238 Castle Biosciences shares in Q1 2026, an estimated $204K.
  • Raymond James Financial first reported a position in Castle Biosciences in Q2 2025 and held it in 2 quarters.
  • Raymond James Financial's Castle Biosciences position peaked at $204K in Q4 2025.
  • 186 funds tracked by Wall St. Rank held Castle Biosciences as of Q1 2026.

Based on Raymond James Financial's 13F filing for Q1 2026, filed 14 May 2026.